Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients
Watch the video and learn on how to leverage incremental clinical benefit to patients with recent ACS and LDL-C near 70 mg/dL from optimized statin therapy and PCSK9i.
-(1).jpg/jcr:content/image%20(58)%20(1).jpg)
Related articles
MAT-BH-2200017/v2/Jun 2023